Efficacy and safety of dolutegravir-rilpivirine for maintenance of virological suppression in adults with HIV-1: 100-week data from the randomised, open-label, phase 3 SWORD-1 and SWORD-2 studies.

Aboud M, Orkin C, Podzamczer D, et al. Lancet HIV. 2019;6(9):e576-e587.

HIV and substance use disorder: role of the HIV physician.

Bositis CM, St. Louis J. Infect Dis Clin North Am. 2019;33(3):835-855.

Durable efficacy of dolutegravir plus lamivudine in antiretroviral treatment-naive adults with HIV-1 infection: 96-week results from the GEMINI-1 and GEMINI-2 randomized clinical trials.

Cahn P, Madero JS, Arribas JR, et al. J Acquir Immune Defic Syndr. 2020;83(3):310-318.

Implementation of a rapid entry program decreases time to viral suppression among vulnerable persons living with HIV in the southern United States.

Colasanti J, Sumitani J, Mehta CC, et al. Open Forum Infect Dis. 2018;5(6):ofy104. 

HIV viral load and transmissibility of HIV infection: undetectable equals untransmittable.

Eisinger RW, Dieffenbach CW, Fauci AS. JAMA. 2019;321(5):451-452.

Randomized switch to B/F/TAF in African American adults with HIV.

Hagins DP, Kumar PN, Saag M, et al. Conference on Retroviruses and Opportunistic Infections (CROI); March 8-11, 2020; Boston, MA. Abstract 36.

Linkage and antiretroviral therapy within 72 hours at a Federally Qualified Health Center in New Orleans.

Halperin J, Butler I, Connor K, et al. AIDS Patient Care STDS. 2018;32(2):39-41.

Switching to doravirine/lamivudine/tenofovir disoproxil fumarate (DOR/3TC/TDF) maintains HIV-1 virologic suppression through 48 weeks: results of the DRIVE-SHIFT Trial.

Johnson M, Kumar P, Molina JM, et al; for the DRIVE-SHIFT Study Group. J Acquir Immune Defic Syndr. 2019;81(4):463-472.

Switching to fixed-dose bictegravir, emtricitabine, and tenofovir alafenamide from dolutegravir plus abacavir and lamivudine in virologically suppressed adults with HIV-1: 48 week results of a randomised, double-blind, multicentre, active-controlled, phase 3, non-inferiority trial.

Molina JM, Ward D, Brar I, et al. Lancet HIV. 2018;5(7):e357-e365.

Depression in HIV infected patients: a review.

Nanni MG, Caruso R, Mitchell AJ, et al. Curr Psychiatry Rep. 2015;17(1):530.

Long-acting cabotegravir and rilpivirine after oral induction for HIV-1 infection.

Orkin C, Arasteh K, Górgolas Hernández-Mora M, et al. N Engl J Med. 2020;382(12):1124-1135.

The effect of same-day observed initiation of antiretroviral therapy on HIV viral load and treatment outcomes in a US public health setting.

Pilcher CD, Ospina-Norvell C, Dasgupta A, et al. J Acquir Immune Defic Syndr. 2017;74(1):44-51.

Weight gain following initiation of antiretroviral therapy: risk factors in randomized comparative clinical trials.

Sax PE, Erlandson KM, Lake JE, et al. Clin Infect Dis. 2020;71(6):1379-1389.

Switching to bictegravir, emtricitabine, and tenofovir alafenamide in virologically suppressed adults with HIV.

Sax PE, Rockstroh JK, Luetkemeyer AF, et al. Clin Infect Dis. 2020. [Epub ahead of print].

Long-acting cabotegravir and rilpivirine for maintenance of HIV-1 suppression.

Swindells S, Andrade-Villanueva JF, Richmond GJ, et al. N Engl J Med. 2020;382(12):1112-1123.

Efficacy and safety of switching to dolutegravir/lamivudine fixed-dose two-drug regimen versus continuing a tenofovir alafenamide-based three- or four-drug regimen for maintenance of virologic suppression in adults with HIV-1: phase 3, randomized, non-inferiority TANGO Study.

van Wyk J, Ajana F, Bisshop F, et al. Clin Infect Dis. 2020. [Epub ahead of print].

Update on neural tube defects with antiretroviral exposure in the Tsepamo study, Botswana.

Zash R, Holmes L, Diseko M, et al. J Int AIDS Soc. 2020;23(suppl 4):183-184. Abstract OAXLB0102.